Tag Archives: Treatment

Perspectives: New TB Treatment Creates Hope For Millions Living In Poorer Countries, But More Work Needs To Be Done On Novel Antibiotics

Editorial pages express views about the breakthrough in treatment for hard-to-cure Tuberculosis cases. The Wall Street Journal: A New Dose Of Hope In The Battle With Tuberculosis Tuberculosis is the world’s deadliest infectious disease: Between 2007 and 2017, an estimated 94.5 million people caught tuberculosis, and more than 14 million died from it. Rising numbers… Read More »

FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Print this page SUMMIT, N.J.–(BUSINESS WIRE) July 19, 2019 — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the… Read More »